Clinical Trial Detail

NCT ID NCT03528694
Title Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

transitional cell carcinoma

Therapies

BCG solution + Durvalumab

BCG solution

Age Groups: senior adult

No variant requirements are available.